WHAT IS CLAIMED IS:

1. Use of a synthetic peptide for manufacturing a medicament for treating a disease, disorder or condition related to inflammation, wherein the synthetic peptide consists of 7 consecutive amino acid residues set forth as $X_1X_2X_3X_4X_5X_6X_7$ (SEQ ID NO: 1), wherein,

X_1 is alanine (A), aspartic acid (D), asparagine (N), leucine (L), phenylalanine (F), or valine (V);

X_2 is alanine (A), isoleucine (I), leucine (L), or valine (V);

X_3 is phenylalanine (F), tyrosine (Y) or tryptophan (W);

X_4 is arginine (R) or lysine (K);

X_5 is valine (V), methionine (M), isoleucine (I), leucine (L), or glutamine (Q);

X_6 is arginine (R), glutamine (Q), lysine (K) or proline (P);

X_7 is serine (S) or threonine (T); and

each X_2, X_3, X_4, X_6 and X_7 are independently L-form amino acid residues:

wherein the synthetic peptide has the amino acid sequence of SEQ ID NO: 2, 3, 4, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21; and

the disease, disorder or condition related to inflammation is selected from the group consisting of, autoimmune disease, acne rosacea, peptic ulcers, gastritis, gout, gouty arthritis, arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, ulcers, chronic bronchitis, asthma, allergy, allergic conjunctivitis, acute lung injury, pulmonary inflammation, airway hyper-responsiveness, vasculitis, septic shock, psoriasis, atopic dermatitis and eczema.

2. The use of claim 1, wherein the synthetic peptide has the amino acid sequence of SEQ ID NO: 2, and one of X_1 and X_5 is a D-form amino acid residue.

3. The use of claim 2, wherein X_1 is in D-form.

4. The use of claim 2, wherein X_5 is in D-form.

5. The use of claim 1, wherein the autoimmune disease is any of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, transplant rejection, immune disorder associated with graft transplantation rejection, benign lymphocytic angiitis, lupus erythematosus, Hashimoto's thyroiditis, primary myxedema, Graves's disease, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, insulin dependent diabetes mellitis, Good pasture's

syndrome, muasthenia gravis, pemphigus, sympathetic ophthalmia, autoimmune uveitis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic hepatitis, ulcerates colitis, Sjogren's syndrome, Wegener's sarcoidosis, antiphospholipid syndrome, inflammatory myopathy, polyarteritis, rheumatic disease, polymyositis, scleroderma, mixed connective tissue disease, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, collagen disease, chronic polyarthritis, psoriasis arthropathica, ankylosing spondylitis, juvenile rheumatoid arthritis, periarthritis humeroscapularis, panarteriitis nodosa, progressive systemic scleroderma, arthritis urica, dermatomyositis, muscular rheumatism, myositis, myogelosis, and chondrocalcinosis, thyroiditis, allergic oedema, granulomas, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or amyotrophic lateral sclerosis (ALS).

6. The use of claim 5, wherein the autoimmune disease is psoriasis.

7. The use of claim 5, wherein the autoimmune disease is rheumatoid arthritis.

8. The use of claim 1, wherein the disease, disorder or condition related to inflammation is asthma.

9. The use of claim 1, wherein the disease, disorder or condition related to inflammation is allergic conjunctivitis.